CHA Biotech and Novartis Korea Partner to Establish Open Innovation Center
Establishing a Support System for Startup Discovery and Global Expansion
K-Bio CIC to Launch in the Second Half of the Year within Pangyo CGB
Integrated Support from R&D to Clinical Development and Manufacturing
CHA Biotech and Novartis Korea are launching an open innovation partnership to discover promising bio startups and support their global expansion.
At the MOU event between Cha Biotech and Novartis Korea held on the 23rd, officials are taking a group photo. From left to right: Youngjin Heo, Head of Global BD Division at Cha Biotech Group; Eunyoung Yang, Vice President; Wonpil Kim, Executive Director at Novartis Korea; Dasom Baek, Director. Cha Biotech
View original imageOn March 23, CHA Biotech announced that it had signed a memorandum of understanding (MOU) with Novartis Korea to establish the "K-Bio CIC Open Innovation Center." The two companies plan to jointly support the discovery of promising bio companies' technologies and their commercialization.
Under this agreement, they will collaborate on technology scouting, mentoring and educational programs, and networking events. They will also seek investment opportunities and global partnerships for startups.
The center will be located within the CGB (Cell Gene Bioplatform), which is currently under development in the Second Pangyo Techno Valley. It will cover an area of approximately 10,000 square meters and is scheduled to begin operations in the second half of 2026.
CGB is being established as a bio cluster focused on cell and gene therapy, encompassing research and development, clinical trials, manufacturing, and business development functions. CDMO facilities, GMP production facilities, and research infrastructure are being constructed.
The K-Bio CIC Open Innovation Center will operate as a platform offering shared laboratories, a global network, and integrated clinical and manufacturing support. It is designed to help startups advance from early-stage research to clinical development and commercialization.
CHA Biotech plans to build a support system spanning from technology validation to commercialization, leveraging its proprietary cell library and global manufacturing network. Novartis Korea will participate in the center’s programs, providing technical advice, mentoring, and networking opportunities. Through these efforts, the two companies aim to expand opportunities for discovering promising technologies and fostering collaboration.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
CHA Biotech CEO Chawon Tae stated, "Through open innovation collaboration, we will strengthen connections between global pharmaceutical companies and startups." Yoo Byungjae, CEO of Novartis Korea, said, "We will support the global expansion of domestic bio companies."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.